Ionis

Delivering innovative medicines to patients where no others have proven effective or existed. See our community guidelines:

[Ionis @ionispharma]

Today we announced a new update to our Board of Directors. Read the full press release: https://t.co/kmMV9aP7uF
$IONS

[Ionis @ionispharma]

This month, we are presenting new analyses from our Phase 3 studies of our investigational treatment for severe hypertriglyceridemia (#sHTG) at #ADASciSessions, #NLASessions and #ENDO2026. Read more: https://t.co/xb129V2SkZ
$IONS

[Ionis @ionispharma]

Today, with our partner @GSK, we announced positive results from two Phase 3 studies for an investigational medicine for the treatment of chronic hepatitis B (CHB), presented at #EASLCongress 2026. Learn more: https://t.co/6jPgnVS41K @EASLnews

[Ionis @ionispharma]

EAC brings together allergists, immunologists & industry leaders focused on advancing care for people living w/serious diseases, including hereditary angioedema. We're sharing insights on RNA-targeted technology & our work to advance innovation in #HAE https://t.co/XHMKJQGj0G

[Ionis @ionispharma]

Today, with @Biogen, we shared topline results from the Phase 2 study of our investigational ASO for the potential treatment of early #AlzheimersDisease. Read more: https://t.co/bYGfpMdAmR $IONS

[Ionis @ionispharma]

Today we reported Q1 2026 financial results. Read more about our updates and tune in live to the webcast today at 8:30 AM ET to hear our first quarter highlights: https://t.co/vrEbO84sov
$IONS

[Ionis @ionispharma]

Today, with our partner @GSK, we announced an investigational medicine for the treatment of chronic hepatitis B was accepted by the U.S. FDA for Priority Review and awarded Breakthrough Therapy designation. https://t.co/APDriV4yRh
$IONS

[Ionis @ionispharma]

Congrats to Dr. Tim Miller of Washington University on receiving the Potamkin Prize for his work validating MAPT as an ASO target. It was an honor to collaborate on this breakthrough in neurodegenerative disease research.

[Ionis @ionispharma]

Today’s data reflect our ongoing commitment to developing RNA‑targeted medicines that may help people living with Alexander disease. We are deeply grateful to the patients, families, investigators and broader community who have made this research possible. https://t.co/f91k5TSN75

[Ionis @ionispharma]

Today, we announced additional positive results from the pivotal study of our investigational medicine for Alexander disease (AxD). Read more: https://t.co/f91k5TSfhx
$IONS

[Ionis @ionispharma]

Headed to the 2026 #AANAM? Make sure to stop by booth 1824 to meet some of our amazing Ionis team members and learn about our latest innovations in #neurology.
$IONS

[Ionis @ionispharma]

Save the date for our Q1 2026 earnings webcast. Register now and tune in live on April 29 at 8:30 am ET: https://t.co/xhHKMGSUDZ
$IONS

[Ionis @ionispharma]

With National Triglycerides Day on 3/28, we are reminded of the importance of continued education and innovation for people living with severe hypertriglyceridemia (sHTG). We look forward to connecting at @ACCinTouch Scientific Sessions. HCPs, learn more: https://t.co/z33rgPovbh

[Ionis @ionispharma]

This #AmyloidosisAwarenessMonth, learn about Charles’ unique perspective as a retired cardiologist on what it’s like to live with transthyretin amyloid cardiomyopathy (ATTR-CM). Read more: https://t.co/PMm3WKdNhv

[Ionis @ionispharma]

We are pleased to announce that the U.S. FDA has accepted for Priority Review our New Drug Application (NDA) for our investigational Alexander disease (AxD) treatment. Read more here: https://t.co/UNZFh2PQgN
$IONS

[Ionis @ionispharma]

Today we announced changes to our Board of Directors. Read the full press release: https://t.co/UXoBwE0sBt

[Ionis @ionispharma]

On #RareDiseaseDay, we honor the strength, courage and resilience of the patients, families, caregivers, researchers and clinicians who make up the rare disease community. We are proud to work with you and learn from you every step of the way. #ShowYourStripes

[Ionis @ionispharma]

At the @AAAAI 2026 Annual Meeting, we’ll be sharing new data supporting our RNA-targeted prophylactic medicine for hereditary angioedema (#HAE) across eight presentations.

Learn more: https://t.co/98LFB6FJsC

#RareDisease #AAAAI2026

[Ionis @ionispharma]

The U.S. FDA has accepted for Priority Review our supplemental New Drug Application (sNDA) for our investigational severe hypertriglyceridemia (sHTG) treatment. More details here: https://t.co/VpRHPMLrfY
$IONS

[Ionis @ionispharma]

Today we reported Q4 and full year 2025 financial results. Read more about our updates and tune in live to the webcast today at 8:30 AM ET to hear our fourth quarter and full year highlights: https://t.co/hXn1SpFzWA
$IONS